Bhasker V. Shetty

Viracept (Nelfinavir Mesylate, AG1343):  A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease

Stephen W. Kaldor, Vincent J. Kalish, Jay F. Davies et al. · Journal of Medicinal Chemistry · 1997 · 620 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

Kanyin E. Zhang, Amy K. Patick, Bradley M. Kerr et al. · Antimicrobial Agents and Chemotherapy · 2001 · 121 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.

James H. Lillibridge, Bai Hong Liang, Bradley M. Kerr et al. · PubMed · 1998 · 107 citations

Medicine, Pharmacokinetics, Pharmacology +17

AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies

S. E. Webber, Charlotte A. Bartlett, Theodore J. Boritzki et al. · Cancer Chemotherapy and Pharmacology · 1996 · 91 citations

Life Sciences, Medicinal Chemistry, Molecular Biology +5

High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma

James M Wilkinson, Daniel G Naret, Valerie L Daniels et al. · Journal of Chromatography B Biomedical Sciences and Applications · 1997 · 71 citations

Pharmacy, Infectious Diseases, Pharmacokinetics +14